Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Pfizer has agreed to pay up to $250mn to settle more than 10,000 US lawsuits over cancer risks associated ...
Pfizer (NYSE:PFE) has reportedly agreed to pay up to $250M to settle more than 10,000 U.S. lawsuits alleging that the company concealed cancer risks associated with its now-discontinued heartburn ...
London: Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on Thursday.
In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc. PFE has agreed to pay up to $250 million. What Happened: The settlement, disclosed in a Delaware ...
Along with GSK and Pfizer, Sanofi and Boehringer Ingelheim GmbH have been sued by consumers. After the federal cases were ...
Pfizer has agreed to pay between $200m to $250m to settle more than 10,000 US lawsuits over cancer risks associated with Zantac, Financial Times reports, citing two unidentified people briefed on the ...
(Reuters) -Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on ...
GSK plc confirms that the company has taken the first step to seek appeal of the recent Daubert ruling, made by the Delaware Superior Court, which permits plaintiff expert testimony as part of the ...
(Reuters) -Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on ...